CoChat
Sign Up
Cited by 33

The DOI matches its Crossref record.

Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine

Harris, Andrew C., Boelens, Jaap J., Ahn, Kwang Woo, Fei, Mingwei, Abraham, Allistair, Artz, Andrew, Dvorak, Christopher, Frangoul, Haydar, Freytes, Cesar, Gale, Robert Peter, Hong, Sanghee, Lazarus, Hillard M., Loren, Alison, Mineishi, Shin, Nishihori, Taiga, O’Brien, Tracey, Williams, Kirsten, Pasquini, Marcelo C., Levine, John E.·2018·Blood Advances
DOI 10.1182/bloodadvances.2018016956
Open this paper in CoChat — free account

Abstract

Key Points: Children receiving BuFlu for nonmalignant conditions experienced less toxicity than those receiving BuCy, but survival was comparable. Children with malignancy had shorter postrelapse survival with BuFlu than BuCy; transplant-related mortality and relapse were similar.

Overview

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2018016956

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 28

  1. McDonald, 2010, Hepatobiliary complications of hematopoietic cell transplantation, 40 years on, Hepatology, 51, 1450, 10.1002/hep.23533 · DOI
  2. Ozkaynak, 1991, Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome, Bone Marrow Transplant, 7, 467
  3. Sencer, 1993, Hemorrhagic cystitis after bone marrow transplantation. Risk factors and complications, Transplantation, 56, 875, 10.1097/00007890-199310000-00020 · DOI
  4. Gandhi, 2002, Cellular and clinical pharmacology of fludarabine, Clin Pharmacokinet, 41, 93, 10.2165/00003088-200241020-00002 · DOI
  5. Andersson, 2008, Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS, Biol Blood Marrow Transplant, 14, 672, 10.1016/j.bbmt.2008.03.009 · DOI
  6. Chae, 2007, New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2, Bone Marrow Transplant, 40, 541, 10.1038/sj.bmt.1705770 · DOI
  7. Liu, 2013, Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study, J Hematol Oncol, 6, 15, 10.1186/1756-8722-6-15 · DOI
  8. Russell, 2002, Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes, Biol Blood Marrow Transplant, 8, 468, 10.1053/bbmt.2002.v8.pm12374451 · DOI
  9. Bartelink, 2014, Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity, Biol Blood Marrow Transplant, 20, 345, 10.1016/j.bbmt.2013.11.027 · DOI
  10. Giralt, 2009, Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research, Biol Blood Marrow Transplant, 15, 367, 10.1016/j.bbmt.2008.12.497 · DOI
  11. Przepiorka, 1995, 1994 Consensus Conference on Acute GVHD Grading, Bone Marrow Transplant, 15, 825
  12. Lee, 2002, Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse, Blood, 100, 406, 10.1182/blood.V100.2.406 · DOI
  13. Shulman, 1980, Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients, Am J Med, 69, 204, 10.1016/0002-9343(80)90380-0 · DOI
  14. Ben-Barouch, 2016, Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis, Bone Marrow Transplant, 51, 232, 10.1038/bmt.2015.238 · DOI · Paper page
  15. Fedele, 2014, Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen, Clin Lymphoma Myeloma Leuk, 14, 493, 10.1016/j.clml.2014.04.006 · DOI
  16. Lei, 2015, Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis, Int J Clin Exp Med, 8, 12064
  17. Rambaldi, 2015, Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial, Lancet Oncol, 16, 1525, 10.1016/S1470-2045(15)00200-4 · DOI
  18. de Lima, 2004, Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS, Blood, 104, 857, 10.1182/blood-2004-02-0414 · DOI
  19. Shah, 2014, Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 20, 1033, 10.1016/j.bbmt.2014.03.028 · DOI
  20. Bitan, 2017, Personalized prognostic risk score for long-term survival for children with acute leukemia after allogeneic transplantation, Biol Blood Marrow Transplant, 23, 1523, 10.1016/j.bbmt.2017.05.011 · DOI
  21. Lange, 2008, Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children’s oncology group, Blood, 111, 1044, 10.1182/blood-2007-04-084293 · DOI
  22. Smith, 2005, Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891, Leukemia, 19, 2054, 10.1038/sj.leu.2403925 · DOI
  23. Harris, 2013, Advances in predicting acute GVHD, Br J Haematol, 160, 288, 10.1111/bjh.12142 · DOI
  24. Andersson, 2002, Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia, Biol Blood Marrow Transplant, 8, 477, 10.1053/bbmt.2002.v8.pm12374452 · DOI
  25. Ljungman, 1997, High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients, Bone Marrow Transplant, 20, 909, 10.1038/sj.bmt.1700994 · DOI
  26. Slattery, 1995, Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics, Bone Marrow Transplant, 16, 31
  27. Pidala, 2010, Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia, J Hematol Oncol, 3, 36, 10.1186/1756-8722-3-36 · DOI
  28. Bartelink, 2016, Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis, Lancet Haematol, 3, e526, 10.1016/S2352-3026(16)30114-4 · DOI

Cited by

Metadata

Authors
Harris, A. C., Boelens, J. J., Ahn, K. W., Fei, M., Abraham, A., Artz, A., Dvorak, C., Frangoul, H., Freytes, C., Gale, R. P., Hong, S., Lazarus, H. M., Loren, A., Mineishi, S., Nishihori, T., O’Brien, T., Williams, K., Pasquini, M. C., & Levine, J. E.
Affiliations
  • Pediatric Blood and Marrow Transplant Program, Univeristy of Utah, Salt Lake City, UT;
  • Blood and Marrow Transplantation Program, Princess Maximax Center, Utrecht, The Netherlands;
  • Center for International Blood and Marrow Transplant Research, Department of Medicine, and
  • Division of Blood and Marrow Transplantation, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC;
  • Section of Hematology/Oncology, University of Chicago School of Medicine, Chicago, IL;
  • Department of Pediatrics, University of California, San Francisco Medical Center, San Francisco, CA;
  • The Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute, Nashville, TN;
  • Texas Transplant Institute, San Antonio, TX;
  • Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom;
  • Division of Hematology/Oncology, University of Washington, Seattle, WA;
  • Seidman Cancer Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH;
  • Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;
  • Penn State Hershey Medical Center, Hershey, PA;
  • Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;
  • Blood & Marrow Transplant Program, Kids Cancer Centre, Sydney Children’s Hospital, Sydney, Australia;
  • Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; and
  • Mount Sinai Medical Center, New York, NY
ORCID
Venue
Blood Advances
Publisher
American Society of Hematology
Published
2018-05-29
Volume
2
Issue
11
Pages
1198-1206
ISSN
  • 2473-9529
  • 2473-9537
DOI
10.1182/bloodadvances.2018016956
Cited by
33
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review